KRT88P and hepatocellular carcinoma: In a recently completed study in South Africa, it was shown that the risk of a HBsAg-negative, HBV DNA-positive individual (with or without anti-HBc) developing HCC was 5.10 (2.06–12.62) compared to a risk of 34.48 (16.26–73.13) in HBsAg-positive individuals (with or without anti-HBc), adjusted for age group, sex, HCV serostatus, country of birth, and HIV status [30].